TROKENDI XR Drug Patent Profile
✉ Email this page to a colleague
When do Trokendi Xr patents expire, and what generic alternatives are available?
Trokendi Xr is a drug marketed by Supernus Pharms and is included in one NDA. There are ten patents protecting this drug and two Paragraph IV challenges.
This drug has eleven patent family members in eight countries.
The generic ingredient in TROKENDI XR is topiramate. There are twenty-six drug master file entries for this compound. Fifty-three suppliers are listed for this compound. Additional details are available on the topiramate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Trokendi Xr
A generic version of TROKENDI XR was approved as topiramate by ACCORD HLTHCARE on March 27th, 2009.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TROKENDI XR?
- What are the global sales for TROKENDI XR?
- What is Average Wholesale Price for TROKENDI XR?
Summary for TROKENDI XR
International Patents: | 11 |
US Patents: | 10 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 103 |
Clinical Trials: | 1 |
Patent Applications: | 5,077 |
Drug Prices: | Drug price information for TROKENDI XR |
Drug Sales Revenues: | Drug sales revenues for TROKENDI XR |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for TROKENDI XR |
What excipients (inactive ingredients) are in TROKENDI XR? | TROKENDI XR excipients list |
DailyMed Link: | TROKENDI XR at DailyMed |
Recent Clinical Trials for TROKENDI XR
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Supernus Pharmaceuticals, Inc. | Phase 2 |
University of Minnesota - Clinical and Translational Science Institute | Phase 2 |
University of Minnesota | Phase 2 |
Pharmacology for TROKENDI XR
Mechanism of Action | Cytochrome P450 2C19 Inhibitors Cytochrome P450 3A4 Inducers |
Physiological Effect | Decreased Central Nervous System Disorganized Electrical Activity |
Paragraph IV (Patent) Challenges for TROKENDI XR
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
TROKENDI XR | Extended-release Capsules | topiramate | 25 mg, 50 mg, and 100 mg | 201635 | 1 | 2014-05-12 |
TROKENDI XR | Extended-release Capsules | topiramate | 200 mg | 201635 | 1 | 2014-04-03 |
US Patents and Regulatory Information for TROKENDI XR
TROKENDI XR is protected by twenty US patents.
Patents protecting TROKENDI XR
Sustained-release formulations of topiramate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY
Sustained-release formulations of topiramate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
Sustained-release formulations of topiramate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF EPILEPSY
Sustained-release formulations of topiramate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
Sustained-release formulations of topiramate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
Sustained-release formulations of topiramate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF EPILEPSY
Sustained-release formulations of topiramate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
Sustained-release formulations of topiramate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF EPILEPSY
Sustained-release formulations of topiramate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
Sustained-release formulations of topiramate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF EPILEPSY
Sustained-release formulations of topiramate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF EPILEPSY
Sustained-release formulations of topiramate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
Sustained-release formulations of topiramate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY
Sustained-release formulations of topiramate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
Sustained-release formulations of topiramate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
Sustained-release formulations of topiramate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY
Sustained-release formulations of topiramate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
Sustained-release formulations of topiramate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY
Sustained-release formulations of topiramate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
Sustained-release formulations of topiramate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Supernus Pharms | TROKENDI XR | topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 201635-004 | Aug 16, 2013 | AB1 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
Supernus Pharms | TROKENDI XR | topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 201635-003 | Aug 16, 2013 | AB1 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
Supernus Pharms | TROKENDI XR | topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 201635-003 | Aug 16, 2013 | AB1 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
Supernus Pharms | TROKENDI XR | topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 201635-003 | Aug 16, 2013 | AB1 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Supernus Pharms | TROKENDI XR | topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 201635-004 | Aug 16, 2013 | AB1 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
Supernus Pharms | TROKENDI XR | topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 201635-002 | Aug 16, 2013 | AB1 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for TROKENDI XR
See the table below for patents covering TROKENDI XR around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Canada | 2618240 | FORMULATIONS DE TOPIRAMATE A LIBERATION PROLONGEE (SUSTAINED-RELEASE FORMULATIONS OF TOPIRAMATE) | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 2008061226 | ⤷ Sign Up | |
European Patent Office | 2394643 | Formulations à libération prolongée de topiramate (Sustained-release formulations of topiramate) | ⤷ Sign Up |
Spain | 2312308 | ⤷ Sign Up | |
Spain | 2555066 | ⤷ Sign Up | |
Mexico | 2009001711 | FORMULACIONES DE LIBERACION SOSTENIDA DE TOPIRAMATO. (SUSTAINED-RELEASE FORMULATIONS OF TOPIRAMATE.) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for TROKENDI XR
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2317997 | 2190050-1 | Sweden | ⤷ Sign Up | PRODUCT NAME: PHENTERMINE AND TOPIRAMATE; NAT. REG. NO/DATE: 59574-59577 20210617; FIRST REG.: IS IS/1/21/018/01-04 20210212 |
0138441 | SPC/GB95/028 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: TOPIRAMATE; REGISTERED: UK 0242/0301 19950718 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |